We have all heard the warnings that the rate of avoidable medical errors is staggeringly high, with estimations of hundreds of thousands of preventable deaths annually in the US. Deaths from medical error has even been referred to by some as an epidemic. These reports have become viral in their reach by infiltrating the lay […]

Small cell lung cancer (SCLC) is a devastating diagnosis, and new therapeutic options are desperately needed in this setting. Previously, first-line treatment of extensive-stage SCLC was limited to combination chemotherapy, which is associated with modest overall survival (OS), but inroads have been made with the application of immune checkpoint inhibitor antibodies to this setting. Immunotherapy […]

On June 18, 2019, the United States Food and Drug Administration granted accelerated approval to the PD-1 inhibitor pembrolizumab for use as a monotherapy in the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least 1 other line of therapy. This approval was […]

Chimeric antigen receptor (CAR)-modified T cells have become an important treatment option for some patients with hematologic malignancies, including non-Hodgkin lymphoma and acute leukemias. However, CAR T-cell treatment can be associated with cytokine release syndrome (CRS), which limits its utility by restricting administration only to experienced centers capable of managing this potentially fatal event. In […]

After some of the important 2019 conferences have come to an end, it’s time to reevaluate your product’s or corporate messaging and decide how it fits within the trending insights and newsworthy industry knowledge you gathered from your experiences. Learning about the appropriate evolution of your marketing message post-congress is key to maintaining its buzz—from […]

Mutation testing using cell-free (cf) DNA is becoming increasingly common in oncology, particularly as a tool in tumors that commonly have driver mutations, such as non-small cell lung cancer. Circulating cf tumor DNA in the plasma is now routinely being used alongside traditional tissue-based testing to guide treatment selection and detect resistance mutations upon progression. […]

In today’s fast-paced world, it can be hard to schedule in-person meetings with stakeholders. Yet medical companies face more pressure than ever to connect with stakeholders, or risk missing out on valuable networking opportunities. Virtual collaboration platforms have emerged to help fill this gap. Savvy marketers can now use modern technology to meet stakeholders with […]

When life science companies visualize their ideal key opinion leaders (KOLs) for cancer treatments, they typically think of oncologists and/or hematologists. But in their rush to connect with skilled physicians, many pharmaceutical companies in the United States overlook a vital resource: the rest of the oncology care team. Cancer patients don’t receive care from an […]

According to a population study published recently in JAMA Oncology, cancer survivors are more likely to suffer from chronic pain and high-impact chronic pain than the general population. The study evaluated long-term outcomes among 4526 adult cancer survivors included in the US National Health Interview Survey. Chronic pain occurred in 1648 (34.6%) and high-impact chronic […]

Key opinion leaders (KOLs) are important to pharma, as they lend a qualified and esteemed voice to your brand strategy. While industry regulations provide substantial hurdles for pharma communications, KOLs have better engagement with larger physician networks. Traditionally, the value of KOLs was in their ability to move a market. Although this fact hasn’t changed, […]